Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep (NASDAQ: IMMP) announced quality-of-life results from its EFTISARC-NEO Phase II trial, showing stable health status during treatment and improvement after surgery. The investigator-initiated study evaluates efti with pembrolizumab and radiotherapy before surgery in patients with operable soft tissue sarcoma.
Quality of life, a secondary endpoint, showed no statistically significant deterioration on any measured scale during treatment. After surgery, the questionnaire summary score improved 6.0 points, role functioning improved 12.7 points and social functioning improved 8.1 points; fatigue was lower than baseline by up to 14.2 points. All improvements were statistically significant. The trial enrolled 40 patients; 29–38 completed subsequent questionnaires. The previously reported primary endpoint showed median tumour hyalinization/fibrosis, a tissue-change measure, of 51.5% versus a prespecified 35% target in 38 evaluable patients (p<0.001).
Immutep (NASDAQ: IMMP) will present IMP761 Phase I study data at ACR Convergence on November 10, 2026, following late-breaking abstract acceptance.
The poster covers a randomised, placebo-controlled, double-blind first-in-human study in healthy volunteers. IMP761 is an antibody designed to activate LAG-3, an immune-system receptor, to suppress immune responses. The study is being conducted by the Centre for Human Drug Research in Leiden, the Netherlands. Poster LB09 is scheduled for 10:30 AM–12:30 PM ET at the meeting in Orlando, Florida. First interim study data were presented at EULAR in June 2026. The poster will be available on Immutep’s website following the presentation.
Immutep (IMMP) and Monash University secured further ARC support for their LAG-3 research collaboration through a grant awarded to Monash. The Australian Research Council awarded A$652,248 over three years. The project, led by Professor Jamie Rossjohn, will examine how LAG-3, a protein involved in immune regulation, interacts with MHC Class II and influences signalling between immune cells. It will also assess IMP761, an antibody that activates LAG-3, for its effects on binding, interactions at the contact point between immune cells and functional outcomes.
The research builds on the collaboration’s human LAG-3/MHC Class II crystal structure published in December 2024. Immutep will contribute financially to the study. Neither the ARC funding nor Immutep’s contribution is material to the company.
Immutep (NASDAQ: IMMP) has regained compliance with Nasdaq’s minimum bid price requirement, resolving the previously notified deficiency affecting its American Depositary Shares.
Nasdaq’s written notification, dated 12 October 2026, confirmed that the closing bid price was at least US$1.00 per ADS for 10 consecutive business days, from 28 September to 9 October 2026. The matter is now closed. To address the deficiency, Immutep changed its ADS ratio from one ADS representing 10 ordinary shares to one representing 200 ordinary shares, effective 28 September 2026. Its ordinary shares were unaffected and continue trading on the ASX as IMM; its ADSs continue trading on the Nasdaq Global Market as IMMP.
Immutep (IMMP) received an A$856,669 cash rebate from the Australian Federal Government’s tax incentive program for research and development. The rebate covers eligible activities conducted in fiscal 2025. AusIndustry’s approval of an Advance overseas finding made certain overseas research activities eligible alongside Australian activities.
The company will use the non-dilutive funding to advance research on efti and IMP761 and expects its cash to last into the first half of CY2028. Immutep also receives France’s CIR incentive and received its first German Forschungszulage payment in Q4 FY26. Further German payments remain subject to statutory application, assessment and review, with uncertain amounts and timing.
Immutep (IMMP) will change its American Depositary Share (ADS) ratio on 28 September 2026 (US Eastern time). Each ADS will shift from representing ten ordinary shares to representing two hundred ordinary shares, which for ADS holders has the same practical effect as a 1‑for‑20 reverse split of existing ADSs. Approximately 32.8 million ADSs on issue will become approximately 1.64 million ADSs, while the 1,473,721,306 ordinary shares on issue, quoted on the ASX, remain unchanged.
The company states the change is a technical step to address Nasdaq’s US$1.00 minimum bid price requirement ahead of the 26 October 2026 compliance deadline and has no effect on its capital structure, cash position or clinical programs. Fractional ADS entitlements will be aggregated and sold by depositary BNY Mellon, with cash in lieu paid without any fee deduction one to two days after the effective date. The Nasdaq ticker IMMP and the ordinary share ISIN are unchanged, but the ADS CUSIP and ISIN will change.
Immutep (IMMP) is refocusing registration-directed development of eftilagimod alfa (“efti”) on head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS < 1 and neoadjuvant soft tissue sarcoma (STS), following the early discontinuation of the TACTI-004 trial and an ongoing root cause analysis.
The analysis has identified structural and analytical differences between efti manufactured at 200 L scale, which was used in earlier successful Phase I/II studies, and at 2,000 L scale, which was used in TACTI-004. A new 200 L GMP manufacturing run has been contracted. The development focus is underpinned by prior positive clinical data, Fast Track designation in HNSCC, and Orphan Drug Designation in STS. Preparations for new trials have begun, with study start targeted for 2H CY2027, subject to final strategy, regulatory and manufacturing decisions, partnering and resources. Licensing partner Dr. Reddy’s Laboratories supports this approach, and development of autoimmune candidate IMP761 continues.
Immutep (NASDAQ: IMMP) reported Q4 FY26 activities, highlighting new clinical, IP and financial developments. A pooled analysis of five efti trials (592 patients, four tumour types) showed increased lymphocyte counts with efti plus standard of care and a 7.7‑month median overall survival benefit for biological responders versus non‑responders.
The TACTI‑004 Phase III 1L NSCLC trial was discontinued after interim futility; efti arm ORR was 42.9% vs 55.1% for control, with no new safety signals and root‑cause work ongoing. INSIGHT‑003 reported median OS of 30.9 months, EFTISARC‑NEO met its primary immune‑activation objective and efti received FDA orphan drug designation in soft tissue sarcoma. First‑in‑human IMP761 data met its primary safety endpoint and showed significant pharmacodynamic activity. Immutep ended the quarter with A$68.87 million in cash, cash equivalents and term deposits, has implemented cost‑reduction measures, and expects its cash runway to extend into H1 CY28.
Immutep (NASDAQ: IMMP) announced that an abstract from the investigator-initiated Phase II EFTISARC-NEO trial of its MHC Class II agonist eftilagimod alfa (efti) in soft tissue sarcoma has been accepted as an ePoster for the ESMO Congress 2026, held 23–27 October 2026 in Madrid, Spain.
The abstract focuses on health-related quality of life (HRQoL) during neoadjuvant treatment with efti, pembrolizumab and radiotherapy. It will be available online on the ESMO website from 00:05 CEST on 19 October 2026 (Presentation #3788eP), with the presentation later accessible on Immutep’s website. The first author is Dr. Pawel Teterycz from the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw.
Immutep (NASDAQ: IMMP) announced that the United States Patent and Trademark Office has granted a new patent (No. 12,673,088) titled “Combined Preparations for the Treatment of Cancer or Infection.” This is the fourth U.S. patent in Immutep’s series covering eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors.
The patent protects methods for treating cancer using efti with anti-PD-1 or anti-PD-L1 antibodies, or their fragments, and expires on 20 January 2036. According to Immutep, the grant strengthens its intellectual property estate for efti combinations and supports future development and business development opportunities.